Terms: = Prostate cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Clinical Outcome
12 results:
1. Methylation-dependent and -independent roles of ezh2 synergize in CDCA8 activation in prostate cancer.
Yi Y; Li Y; Li C; Wu L; Zhao D; Li F; Fazli L; Wang R; Wang L; Dong X; Zhao W; Chen K; Cao Q
Oncogene; 2022 Mar; 41(11):1610-1621. PubMed ID: 35094010
[TBL] [Abstract] [Full Text] [Related]
2. A concise review on the role of BDNF-AS in human disorders.
Ghafouri-Fard S; Khoshbakht T; Taheri M; Ghanbari M
Biomed Pharmacother; 2021 Oct; 142():112051. PubMed ID: 34426254
[TBL] [Abstract] [Full Text] [Related]
3. Multifaceted role of the polycomb-group gene ezh2 in hematological malignancies.
Sashida G; Iwama A
Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
[TBL] [Abstract] [Full Text] [Related]
4. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.
Nolan KD; Franco OE; Hance MW; Hayward SW; Isaacs JS
J Biol Chem; 2015 Mar; 290(13):8271-82. PubMed ID: 25670862
[TBL] [Abstract] [Full Text] [Related]
5. Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men.
Kachroo N; Warren AY; Gnanapragasam VJ
BMC Cancer; 2014 Sep; 14():673. PubMed ID: 25227682
[TBL] [Abstract] [Full Text] [Related]
6. DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.
Jacobs C; Tumati V; Kapur P; Yan J; Hong D; Bhuiyan M; Xie XJ; Pistenmaa D; Yu L; Hsieh JT; Saha D; Kim DW
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):729-35. PubMed ID: 24867541
[TBL] [Abstract] [Full Text] [Related]
7. The value of ezh2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.
Wolters T; Vissers KJ; Bangma CH; Schröder FH; van Leenders GJ
BJU Int; 2010 Jul; 106(2):280-6. PubMed ID: 19888978
[TBL] [Abstract] [Full Text] [Related]
8. Concepts of epigenetics in prostate cancer development.
Cooper CS; Foster CS
Br J Cancer; 2009 Jan; 100(2):240-5. PubMed ID: 19002169
[TBL] [Abstract] [Full Text] [Related]
9. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Wei Y; Xia W; Zhang Z; Liu J; Wang H; Adsay NV; Albarracin C; Yu D; Abbruzzese JL; Mills GB; Bast RC; Hortobagyi GN; Hung MC
Mol Carcinog; 2008 Sep; 47(9):701-6. PubMed ID: 18176935
[TBL] [Abstract] [Full Text] [Related]
10. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
Yu J; Yu J; Rhodes DR; Tomlins SA; Cao X; Chen G; Mehra R; Wang X; Ghosh D; Shah RB; Varambally S; Pienta KJ; Chinnaiyan AM
Cancer Res; 2007 Nov; 67(22):10657-63. PubMed ID: 18006806
[TBL] [Abstract] [Full Text] [Related]
11. Biomarker discovery in urogenital cancer.
Said J
Biomarkers; 2005 Nov; 10 Suppl 1():S83-6. PubMed ID: 16298916
[TBL] [Abstract] [Full Text] [Related]
12. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome.
Foster CS; Falconer A; Dodson AR; Norman AR; Dennis N; Fletcher A; Southgate C; Dowe A; Dearnaley D; Jhavar S; Eeles R; Feber A; Cooper CS
Oncogene; 2004 Aug; 23(35):5871-9. PubMed ID: 15184867
[TBL] [Abstract] [Full Text] [Related]
